Logo

Tris Pharma’s Dyanavel XR (amphetamine) Receives US FDA’s Approval for the Treatment of ADHD

Share this

Tris Pharma’s Dyanavel XR (amphetamine) Receives US FDA’s Approval for the Treatment of ADHD

Shots:

  • The approval was based on the P-III study to evaluate Dyanavel XR tablets vs PBO in patients aged 6 to 12yrs. with ADHD
  • The results showed that patients treated with Dyanavel XR ER tablets were bioequivalence to Dyanavel XR ER oral suspension, improvement in ADHD symptom within 1hrs., improvement in mean PERMP-T scores across all post-dose time points measured. Patients with Dyanavel XR oral suspension can switch to the same dose of Dyanavel XR tablets
  • In an exploratory study, Dyanavel XR oral suspension showed an improvement of ADHD symptoms in 30 min. after dosing. Dyanavel XR is a federally controlled substance (CII) & are expected to be available in Q1’22

Ref: Tris Pharma| Image: Tris Pharma

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions